Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
References View all references + Sikiri, P., et al
All products sold by Loti Labs are research chemicals only
Per injection: 2.5 mg twice weekly (5 mg/week total), drawn as ~100 units (1.0 mL) on a U-100 syringe
They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose
US$ 19.99
US$ 28.80
US$ 25.11
US$ 22.27